Business Context and Reporting Period
This Form 8-K was filed by Shuttle Pharmaceuticals Holdings, Inc. on October 10, 2023. The Company is a Delaware corporation and an emerging growth company. The filing serves as a current report to announce a corporate event rather than to provide periodic financial results.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is limited to the announcement of an upcoming investor conference.
Material Changes
No material changes to financial position or operations are reported in this document. The sole material event is the scheduled participation of the Company and its CEO, Dr. Anatoly Dritschilo, in the Lytham Partners Fall 2023 Investor Conference.
Guidance, Outlook, and Management Commentary
- Upcoming Event: The Company will participate in the Lytham Partners Fall 2023 Investor Conference virtually on October 17, 2023.
- Participants: Shuttle Pharmaceuticals Holdings, Inc. and Chief Executive Officer Dr. Anatoly Dritschilo.
- Exhibits: A press release regarding the conference is included as Exhibit 99.1.
Investor Verification Checklist
- Verify the date and time of the Lytham Partners Fall 2023 Investor Conference (October 17, 2023).
- Review the attached press release (Exhibit 99.1) for specific details on the presentation topic or agenda.
- Confirm the Company's status as an emerging growth company for potential reporting exemptions.
- Note that this filing contains no new financial data; refer to the most recent 10-Q or 10-K for financial metrics.